ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

Preclinical research suggests that NRH may be among the most potent and efficient of NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline

LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen's University Belfast for methods of making nicotinamide riboside (NR) and related derivatives, some of the most efficient nicotinamide adenine dinucleotide (NAD+) precursors, and today announced it expanded this patent family with newly granted U.S. Patent 11,584,770 for purity compositions of dihydronicotinamide riboside (NRH) and dihydronicotinic acid riboside (NARH). ChromaDex is continuously evaluating and investigating potential next generation NAD+ precursors, which are molecules at the forefront of the burgeoning healthy aging category, and currently owns and licenses a robust and secure portfolio of over 60 patents relating to Niagen® (patented NR) and other NAD+ precursors. Niagen® is the sole active ingredient in ChromaDex's flagship consumer product, Tru Niagen®, the most efficient and well-studied NAD+ precursor currently in the market. These newly granted composition claims cover the commercially viable form of NRH and NARH, allowing ChromaDex to launch future innovations, and further strengthens ChromaDex's position as the leading NAD+ company.

"There is a great deal of interest in the scientific community around NRH," said Rob Fried, CEO of ChromaDex. "Early studies have shown impressive results as a powerful NAD+ precursor. This patent covers food, dietary supplement and pharmaceutical applications."

NRH has gained considerable attention among NAD+ investigators as preclinical research suggests it is a more efficient and potent inducer of NAD+ over other precursors, and thus may be the most promising NAD+ precursor available (*Molecular Metabolism*, *Journal of Biological Chemistry*). Additionally, a new study conducted by Mayo Clinic suggests that NRH has the potential to promote the inflammatory response in macrophages, white blood cells that seek out and destroy microorganisms, remove dead cells, and stimulate the action of other immune system cells, indicating that NRH may be an important tool to understand the role of NAD+ and NADH metabolism in the immune response (*Frontiers in Immunology*).

U.S. Patent 11,584,770 relates to composition of matter for NRH and NARH (and other reduced analogues of NR and NAR) covering >90% chemical purity and >98% beta purity. The composition claims that have been granted are amongst the strongest patent claims that can be achieved for this NAD+ precursor. This patent will provide ChromaDex protection for

NRH and NARH until 2034.

U.S. Patent 11,584,770 is part of the patent family titled “Methods of Preparing Nicotinamide Riboside and Derivatives Thereof” exclusively licensed from Queen’s University Belfast.

For additional information on the science supporting Niagen® visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to solidification of the Company as a leader in the NAD precursor space, the results and implications of the preclinical research, and the value of the patent. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements

are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005348/en/

ChromaDex Media Contact:

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Tom Shumaker, LifeSci Advisors, Managing Director

917-929-7600

tshumaker@lifesciadvisors.com